Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 07/26 10:00:22 pm
58.36 USD   -0.34%
08:55aDJBayer Reports Higher Second-Quarter Profit, Raises Guidance
07/26 MERCK : Announces Fourth-Quarter 2016 Dividend
07/25DJGilead Sales of Hepatitis C Drugs Fall 19%
News SummaryMost relevantAll newsSector news 

Merck & Co., Inc. : Hundreds of Fosamax lawsuits versus Merck ordered readied for trial

share with twitter share with LinkedIn share with facebook
share via e-mail
08/30/2013 | 10:53pm CEST

A federal judge overseeing consolidated litigation against Merck & Co over jaw injuries allegedly caused by the osteoporosis drug Fosamax has ordered hundreds of cases be dispersed to courts across the country for trial.

The decision by U.S. District Judge John Keenan in Manhattan marks an unusual and potentially costly development for Merck.

Companies often find it easier to reach settlements in mass tort cases that are consolidated before one judge.

"It's a big deal as it changes the cost paradigm for Merck exponentially," said Timothy O'Brien, a partner at Levin, Papantonio, Thomas, Mitchell, Rafferty & Proctor and lawyer representing Fosamax plaintiffs.

The judge's order Thursday requires that 200 cases per month be sent to back to courts where they were initially filed, beginning with the oldest ones.

Lainie Keller, a spokeswoman for Merck, said the company "is committed to defending its conduct in regard to Fosamax and has confidence in its defense strategy that has had so much success in the courts."

The cases before Keenan comprised roughly one-fifth of the 5,075 lawsuits pending nationally in federal and state courts related to Fosamax, a one-time blockbuster medication.

Lawsuits alleging that plaintiffs developed osteonecrosis of the jaw from Fosamax were consolidated before Keenan in 2006.

The judge conducted a series of "bellwether" trials, allowing the parties to assess trends and outcomes in similar cases. A series of wins for plaintiffs, for example, can put them in a better position for settlement talks.

The final Fosamax bellwether trial before Keenan ended in February with a $285,000 verdict for plaintiff Rhoda Scheinberg.

Merck lost just one other of the five bellwether trials before Keenan, when a jury in 2010 awarded Florida resident Shirley Boles $8 million, a sum the judge reduced to $1.5 million.

Keenan's order on Friday came after mediation to resolve 370 cases broke down two weeks ago. O'Brien's law firm and another firm represented plaintiffs in those cases.

Another 104 lawsuits brought by another firm could have been added to the talks if a deal on value was reached, O'Brien said.

Lawyers for the plaintiffs had sought to have 300 cases transferred every four months, while Merck sought to have just 100 cases scheduled for discovery over a six-month period.

Merck has benefited from having the litigation consolidated.

Keenan had thrown out 430 cases after he issued an order last November, which Merck had sought, requiring them to put forth expert reports showing scientific proof of their claims.

But in his order Friday, Keenan said Merck's latest proposal would "unnecessarily prolong" the proceedings before him.

Keenan ordered plaintiffs to recommend by October 11 where to sent the first batch of cases.

An order moving so many personal injury cases home at once is rare, O'Brien said. He noted that Merck reached a $4.85 billion settlement with over the painkiller Vioxx in 2007 only after a federal judge threatened a similar order.

"I anticipate Merck will continue talking and seek to resolve the cases," O'Brien said. "The opportunity is there."

The case is In Re Fosamax Products Liability Litigation, U.S. District Court, Southern District of New York, No. 06-md-01789.

(Reporting by Nate Raymond in New York; Editing by Bernard Orr)

By Nate Raymond

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK & CO., INC.
08:55aDJBayer Reports Higher Second-Quarter Profit, Raises Guidance
07/26 MERCK : Announces Fourth-Quarter 2016 Dividend
07/25DJGilead Sales of Hepatitis C Drugs Fall 19%
07/25 MERCK : Receives Breakthrough Therapy Designation from FDA and PRIME Status from..
07/22 MERCK : Data for Merck's Investigational Once-Daily Formulation of ISENTRESS® (r..
07/21 MERCK ANIMAL HEALTH : Receives FDA Approval of BRAVECTO® (fluralaner topical sol..
07/21 MERCK : Provides Regulatory Update on Biologics Licensing Application for Invest..
07/21 MERCK : Patent Issued for Preparation of Crystalline Forms of Dihydropyrazolopyr..
07/21 MERCK : Findings in Pseudohypoparathyroidism and Genetics Reported from Merck & ..
07/21 MERCK : Findings on Enzymes and Coenzymes Reported by Researchers at Merck & Com..
More news
Sector news : Pharmaceuticals - NEC
03:22p GlaxoSmithKline invests 275 million pounds in UK despite Brexit
03:02pDJBAYER : Reports Higher Second-Quarter Profit, Raises Guidance -- 2nd Update
02:33pDJGLAXOSMITHKLINE : Glaxo Swings to Loss on Write-Down But Core Earnings, Revenue ..
02:06pDJELI LILLY : CEO to Retire
02:06pDJGLAXOSMITHKLINE : Swings to Loss
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03:54a JULY BASIC MATERIALS : Coal Tops By Yield But Cellulose, Carbon, Copper, And Che..
07/26 Merck declares $0.46 dividend
07/26 We Remain Cautious On The Kadmon IPO At This Early Stage
07/26 Gilead Sciences - Underneath The Smoke Is Long-Term Potential
07/26 11 Shipping Dogs Lead Industrial Sector By Yield In July, TNP Tops
Financials ($)
Sales 2016 39 492 M
EBIT 2016 13 526 M
Net income 2016 6 428 M
Debt 2016 3 946 M
Yield 2016 3,17%
P/E ratio 2016 25,55
P/E ratio 2017 19,60
EV / Sales 2016 4,19x
EV / Sales 2017 4,18x
Capitalization 161 542 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 61,9 $
Spread / Average Target 6,1%
Consensus details
EPS Revisions
More Estimates Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Michael A. Rosenblatt Chief Medical Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.10.49%161 542
JOHNSON & JOHNSON21.84%344 243
PFIZER INC.14.10%223 368
NOVARTIS AG-5.30%219 971
ROCHE HOLDING LTD.-9.99%218 902
More Results